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SUMMARY 
We have been investigating the new insight in the cancer stem cells (CSCs) by 
developing a CSC model that is derived from induced pluripotent stem cells (iPSCs). The 
evidence of CSCs was widely accepted as small percentage of cell population in tumor that 
have a self-renewal capability and are malignant. Microenvironment is crucial to regulate 
the proliferation, self-renewal ability and differentiation of normal stem cells. By extending 
this concept, microenvironment distorted by cancer cells could affect the diverse directions 
of stem cells and leading to the characteristics of CSCs. Even though CSC shared with 
normal stem cells in the characteristics of maintaining the stemness and differentiation 
potential, multiple genetic and epigenetic regulations are different to acquire the features of 
CSCs. Epigenetic mechanisms, such as DNA methylation, histone modification and non-
coding RNA elements, are involved in stem-cell maintenance and in the regulation of 
differentiation of stem cells. On the other hand, the epigenetic alterations are relating to the 
tumorigenesis with the activation of oncogenes and silencing of tumor suppressor genes.  
 We have succeeded in converting mouse iPSCs (miPSCs) into CSC-Like cells (miPS-
LLCcm) by treating the miPSCs with conditioned medium (CM) of Lewis Lung Carcinoma 
(LLC) cells. miPS-LLCcm cells developed highly angiogenic and malignant 
adenocarcinoma as well as lung metastasis when subcutaneously transplanted into nude 
mice. By the treatment, miPSCs obtained the ability of unlimited growth and the capacity 
to maintain their stemness, while they were allowed to differentiate without LIF. The 
subcutaneous transplantation of the survived cells into the mouse formed malignant 
tumors and metastasized into lung tissues. Thus, we concluded that miPSCs should be 
converted into CSCs without any intended genetic manipulation. Immunohistochemical 
  
vi 
analysis revealed the heterogeneity of the tumors, in which miPS-LLCcm cells should on 
one hand maintain the undifferentiated population expressing GFP and differentiate on the 
other into adenocarcinoma phenotype expressing MUC1. The cells from tumors at primary 
site and metastatic nodules can be maintained in vitro.  
 In order to further confirm the acquisition of CSC-like phenotype, we characterized 
the miPS-LLCcm cells and its derived cells form tumor (Ptdc) and from lung metastatic 
nodules (LMN) with commonly known CSC markers. We evaluated the significantly 
higher expression of ALHD1 and CD44 in the Ptdc and LMN cells. Epithelial to 
mesenchymal transition (EMT) is believed to be the primary mechanisms in the transition 
of cellular stages during development, wound healing and cancer metastasis. The 
upregulated expression of EMT markers in Ptdc cells was suggesting the potential of 
partial and metastable epithelial-to-mesenchymal transition (EMT) phenotype in Ptdc 
cells. 
Since this conversion is triggered only by the factor(s) contained in the conditioned 
medium, we have hypothesized that epigenetic alterations can induce CSCs from normal 
stem cells in the cancer microenvironment. Methylation and demethylation is generally 
considered to silence and activate gene expression, respectively. We tried to evaluate the 
epigenetic changes in early stages of cancer development in this research that has not yet 
been assessed. We traced the development of CSCs by the change of DNA methylation 
levels, which would provide the difference between the miPSCs and derived CSCs.  Then, 
we compared the methylation in miPS-LLCcm, LMN and Ptdc cells with that in miPSC 
by three sets; (1) miPSCs vs miPS-LLCcm cells, (2) miPSCs vs Ptdc cells and (3) miPSCs 
vs LMN cells. All comparisons between the different cell populations were found to 
exhibit hypomethylation as compared to miPSCs and 926, 583 and 1105 differentially 
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methylated regions (DMRs) were identified respectively from the comparisons. DMRs-
associated genes were further identified and segregated into hypo- and hyper-methylated 
genes categories. As the results, hypomethylation was found superior to hypermethylation 
in the CSCs.  
The analysis of KEGG pathways relating to hypomethylated genes revealed the 
several notable pathways important in cancers. Validating certain pathways in the CSCs, 
that are corresponding to DMR-related genes showed the pathways relevant for 
carcinogenesis including Focal adhesion, PI3K-Akt signaling pathway, Calcium signaling 
pathway, Pathway in cancer and Transcriptional misregulation in cancer. Checking the 
upregulated expression of the genes included in the enriched pathways that are concordant 
with hypomethylation showed the trace of candidates relating to oncogenic potential of 
CSCs. The expression of hypomethylated genes relating to PI3K-Akt pathway was found 
significantly high among those of the other genes. We found Pik3r5, which is a regulatory 
subunit of Pik3cg enzyme, as a hypomethylated and highly up-regulated gene relating to 
PI3K-Akt pathway. In the recent reports, the PIK3CG and PIK3R5 were evaluated as a 
potential oncogene that are overexpressed in human cancers leading to oncogenic cellular 
transformation and malignancy. Overexpression of PI3K-Gamma candidates were relating 
to oncogenic potential of the CSC model. Together with the findings, the constitutive 
expression of Pik3r5 was detected by immunoblotting with anti-p101 antibody in miPS-
LLCcm and its derivatives. 
 Activation of PI3K-Akt signaling pathway has been commonly reported as key 
driver of carcinogenesis. The upregulated expression of Pik3r5 should induce the 
activation of Akt resulting in the onset of tumorigenic and metastatic potential of miPS-
LLCcm and Ptdc cells. We assessed the Akt activation with anti-phosphorylated Akt (p-
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Akt) antibody and we found Akt was constitutively activated in miPS-LLCcm, Ptdc and 
LMN cells. Therefore, the hypomethylation of Pik3r5 gene was leading to the up-
regulation and is closely related to the activation/phosphorylation of AKT that is the 
downstream target molecule.  
Significant overall DNA hypomethylation during the conversion activated the 
certain proto-oncogene, with the activation of PI3K-Akt signaling pathway, which 
represent the malignant conversion even without mutations. In our study, we have 
successfully demonstrated the CSCs generated from iPSCs by the treatment with CM from 
cancer derived cells acquired the DNA hypomethylation that might be considered to be 
the new aspect in the early stage of CSCs. 
 
  
 
 
 
 
CHAPTER (1)                                     
GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
3 
1.1. Cancer Stem Cells  
Cancer has been defined as an abnormal growth of cells with 
potential character of invasion or spreading into other parts of body [1]. 
These abnormal cells have the ability to proliferate rapidly, make the 
malignant tumors and invade the native tissue by producing enzymes. By 
contrast, benign tumors don't generally invade and usually push the 
normal tissue to the side [2,3]. There are over 100 types of cancer that can 
affect in human and their symptoms vary depending on the types of tissue, 
such as breast, skin, lung, colon, prostate, and lymphoma [1,4].  
Research into cancers, nowadays, has been changed enormously with 
new and advance technologies. In the area of cancer research, there is still 
questioning how the research projects have been done and how the 
effectiveness of therapies come from the cancer research in the past. To get 
the fundamental progress in treating cancers, the cancer researchers are 
currently focusing into the advanced and more understanding of two 
areas; (a) the genetic underpinning of cancers and (b) the biology of cancers. 
Progressive research outcomes developed many types of cancer treatments 
which depend on the type of cancer and how advanced it is. Conventional 
therapy is widely accepted in cancer treatment and is different from 
alternative or complementary therapies [5,6]. Examples of conventional 
treatment for cancers include chemotherapy, radiation therapy, and 
surgery. With the new findings in the area of cancer research, the cancer 
treatment has also been improved dramatically, such as the adjuvant 
chemotherapy, hormonal therapy, immunotherapy, and target therapy.  
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Recent chemotherapeutic treatment can give the promising results in 
treating the different types of malignancies by combining with surgical 
removal or radiotherapy. After decades of making the drugs to kill 
proliferating tumor cells, the notable progresses in cancer treatment was 
resulted [7,8]. However, cancer researchers are facing the divergent nature 
of cancers such as, chemo-resistance, turning into more tumorigenic form, 
metastasis and cancer relapse. One of the reason is the heterogeneity of 
cancer where certain population of cancer cells have ability to survive 
against several cancer treatments. The chemotherapeutic agents can 
remove and kill the rapidly dividing cells of the bulk tumor but often miss 
the certain population of cells with distinct morphological and functional 
profile [9]. These issues could be explained by the presence of stem cell 
population in the tumor as subgroup of cancer cells. Previous findings 
strongly suggested that these stem cells are responsible for 
chemoresistance and caner relapse [10]. The remaining stem cells are able 
to comprise the whole tumor even in a few number left. These population 
was broadly named as cancer stem cells (CSCs) and thought to be involved 
in driving the cancer [11]. 
Cancer stem cell is normally identified as a cell within a tumor that 
possess the ability to self-renew and to cause the heterogenous lineages of 
tumor cells. There are many hypothesizes of CSC with their different 
points of understanding. The hypothesis has to be tested whether what 
evidence is consistence with it or not and cancer researchers refine the way 
of treating the cancers according their assessment.  
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The cancer research over several decades has been led by the 
mutation theory in that any cell in body could become cancer when it 
acquires a package of mutation [12,13]. Because of single and/or series of 
mutation, single gene or some group of genes, called oncogenes, are 
activated and some genes, called suppressor genes, are inactivated in 
cancer. In some cases, the combination of these two events was also 
involved in the carcinogenesis. Therefore, oncologists defined cancers as 
some kind of genetic mistake. Form this concern, all types of cells in the 
multicellular organisms could become cancer with certain reasons [14]. 
Another concern of cancers was evaluated with the evidence of 
cancer stem cells in the tumor.  In this case, only a certain population of 
cells that have the stem cell properties are really prone to becoming 
malignant [8]. The hypothesis about the cancer stem cells is in an ongoing 
debate. There is still needed to answer whether CSCs represent a mature 
tissue stem cell which has undergone malignant change or whether 
differentiated cells dedifferentiated into stem cell program together with 
the malignancy [15]. Until now, cancer stem cells are purely defined only 
with their capacities of self-renewing and differentiation, considering 
independently from the concept of origin of cancers [7,16].  
Cancers themselves organized through in very similar way to a 
normal organ, but the cells are proliferating abnormally [17]. Normal organ 
is organized in a hierarchy where at the apex of the hierarchy it is the stem 
cell and give rise to the other cells which form the bulk of an organ. In the 
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tumor, it is generally thought that cancer stem is the master cell that gives 
rise to heterogeneity of cancers [7].  
Tumor initiating capacity of CSCs in tumor was shown by serial 
transplantation of limited tumor cells into immunocompromised animal 
models where undifferentiated cancer cells show more than the 
differentiated cancer cells [8,18]. Researchers had been trying to evaluate 
the markers to identify and isolate the population of stem cells from tumor 
cells. Even though the validity of CSC markers depends on different types 
of tissues, and/or modes of tumorigenesis, it is possible to address the 
population of CSC in the tumors with CSC markers detected in specific 
malignancies. Currently, CSCs were identified in human brain, breast, 
prostate, head and neck, pancreas, liver, ovary, and colon cancers, by using 
different markers, such as CD133, EpCAM, CD44, CD24, Lgr5 and ALDH1 
[19]. With many questions about CSCs, the nature and characteristics of 
CSCs become interested and therapeutic CSC-targeting approaches 
popular in past decade of cancer research. Experimental limitation for the 
researchers is that CSCs are very small percentage of tumor cells, and the 
culturing and maintenance of these cells are still difficult [9]. Many 
researchers evaluated the properties and characteristics of CSCs by using 
the model of CSCs that are selected by the help of CSC-markers. The 
evaluations about CSCs are still depending on the validity of markers on 
these cancer types [19,20].  
In conclusion, cancer stem cell is defined as a certain type oncogenic 
cell that have self-renewing and differentiation ability. Their self-renewing 
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properties drives the generation of more CSCs, and differentiation capacity 
generate the bulk of tumors. The metastasis and tumor relapse are also 
related with the properties of CSCs. Due to the properties of CSCs, it is 
very important to provide the therapy that eradicated CSCs completely. 
 
1.2. iPSC-CSC 
The tumor microenvironment (TME) is the cellular environment 
surrounding the tumor in which stromal fibroblasts, immune cells, 
macrophages, endothelial cells, leucocytes, and extracellular matrix exist 
and interact by releasing signaling molecules to promote tumor growth 
and metastasis. It has been reported the significant role of TME in disease 
progression like as cancer, but the clear-cut role has not been understood. 
A major concept of TME is that cancer cells interact closely with the 
surrounding cells, which together form the major construct of the TME 
leading into more complexity of cancer biology. In the case immune cells, 
the factors secreted in TME drive a chronic inflammatory, 
immunosuppressive, and pro-angiogenic environment. By getting 
adaptation in such environment, cancer cells are able to avoid the host 
immunosuppressive action and to get the new properties of metastasis and 
angiogenesis. The aberrant pathological process in tumor 
microenvironment can be related with divergent nature of cancers by 
changing the genetic or epigenetic regulation. Although it is a transient 
effect, it could activate the certain signaling pathways regulating cellular 
CHAPTER 1 
 
8 
proliferation and migration or in the case of stem cells it could be related 
with cell fate determination and differentiation.  
Stem cells are found in certain population in multicellular organisms 
with their special characteristics different from others in the body. Stem 
cells are thought to be in blank state that can develop into cells with 
different specialized functions in different parts of the body during early 
life and growth. Stem cells have been termed as undifferentiated and self-
renewing cells that can divide and make the unrestricted numbers of 
copies of themselves. Difference between stem cells and any other cells in 
the tissues is that when a stem cell divides, one remains by self-renewing 
as stem cell at exactly the same stage of differentiation and the other turns 
into a next stage of the differentiation down to a differentiated cell, such as 
a muscle cell or red blood cell, etc. [16,21].  Generally, type of stem cells can 
be divided into three types; (a) Embryonic stem cells (ESC) (b) Adult stem 
cells (c) Cancer stem cells. Embryonic stem cells are pluripotent, meaning 
they can develop into more than 200 cell types of the adult body and also 
have the ability to replicate indefinitely [22]. Adult stem cells found in 
adults can produce only a limited number of cell types. Cancer stem cells 
(CSCs) are tumor cells that have the principal properties of self-renewal, 
clonal tumor initiation capacity and clonal long-term repopulation 
potential [23].  
Like the normal stem cells, CSCs are believed to reside in their own 
niches [24]. The niches for normal stem cells are crucial for proper 
differentiation of stem cells into certain progenitor cells and differentiated 
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cells. In contrast, the TME could affect on the differentiation of stem cells. 
Seno et.al explained the fate of stem cells distorted by TME using the 
conditioned medium of Lewis Lung Carcinoma (LLC) [24,25]. In their 
hypothesis, mouse induced pluripotent stem cells (miPSCs) should be 
induced to some kinds of progenitor cells, such as hematopoietic cells and 
neural stem cells, differentiating into various phenotypes, such as 
macrophage, monocytes, neural cells, cardiac cells and pancreatic b-cells, 
when they were exposed to the normal niche. On the other hand, they 
hypothesized that CSCs may also be derived from miPS cells only when 
exposure to a malignant niche [Figure 1.1]. 
 
Figure 1.1 The hypothesis of miPSCs conversion into iPS-CSCs. CSCs 
are considered derived from normal stem cells affected by the 
microenvironment being influenced by cancer cells. [25] 
They evaluated the new insight in the CSCs developed in cancer 
microenvironment, by extending the concept that the niche of the normal 
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cells is involved in the differentiation of stem cells into normal tissues. 
While the mouse induced pluripotent stem cells (miPSCs) were allowed to 
differentiate in the presence of cancer conditioned medium, they acquired 
the ability to maintain their stemness and differentiation potential, as well 
as formed malignant tumors with the features of adenocarcinoma and 
metastasized into lung tissues in vivo, considering the sign of CSCs. These 
models of cancer stem cell will provide the great advantages in cancer 
research and its applications in the future. 
In iPS-CSC model, miPSCs were converted into CSCs without any 
intended genetic manipulation. The conversion could be considered 
through the transcriptional or translational changes determined by genetic 
or epigenetic alterations that are promoting tumorigenesis. Furthermore, 
they successfully generated various types CSC models converted from 
iPSCs with the aid of CM of various cancer cell lines such as human 
pancreatic carcinoma cell lines PK-8 cells and KLM-1 cells, human breast 
cancer cell lines T47D cells and BT549 cells, mouse carcinoma cell lines LLC 
cells, P19 cells, B16 cells and MC.E12 cells [14–16]. Anna et.al evaluated 
organ specific feature of xenografts tumors developed from iPS-CSC that 
were converted with conditioned medium of PDAC cells [26]. Furthermore, 
the story and origin of cancer associated fibroblast was explained with iPS-
CSC model developed in the conditioned medium of breast cancer cells 
[27]. The iPS-CSC have differentiated into the fibroblast that support the 
tumorigenesis and metastasis of iPS-CSC. Interestingly, iPS-CSC model 
can also differentiate into the progenies of CSCs containing vascular 
endothelium [24,28].  
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In conclusion, the iPS-CSC is a model of CSCs that can explain biology 
and characteristics of CSC in nature. In addition, CSC generation from 
various kinds of cancer cells could be a source that provide a library of 
CSCs for customized cancer treatment. iPS-CSC model could be used in 
the evaluation of bona fide CSC markers and also the screening of 
chemotherapeutic drugs that are targeting the CSC population, to get 
better therapeutic approach of cancer.  
 
1.3. CSC and Epigenetics 
Carcinogenesis has been explained by the classical cancer initiation 
theory; evolutional accumulation of one or more mutations in a single or a 
few cells resulting in uncontrolled growth [29]. Genetic mutation was 
considered as the major causes of neoplasia [30]. However, it is now 
accepting the involvement epigenetic regulatory mechanisms in 
carcinogenesis. Genetic mutation is responsible for activation of tumor 
driver genes and silencing of tumor suppressors. In the second part, 
disruption of epigenetic regulation is leading to overexpression of 
oncogenes and downregulation of the tumor suppressor genes [31,32]. The 
genetic and epigenetic regulation were viewed as sole reason of abnormal 
gene expression. 
The regulation performed by epigenetic mechanisms includes 
histone modification, chromatin remodeling factors, DNA methylation, 
microRNAs and post–translational modifications. The expression of 
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certain gene was determined by the status of DNA packaging at the 
regulation regions. These regions are normally the promoters and/or 
enhancers and insulators in chromatin. Some regulations were performed 
by the presence of transcription factors and chromatin modifying enzymes 
[33]. 
Without changing in DNA sequence, the ability to change the 
expression of genes is the primary role of epigenetic regulation. The 
epigenetic abnormalities involved in the tumorigenesis is not simple as the 
gain or loss of genes expression because the types of regulation will be 
different and complex depending on the stage and nature of carcinogenesis.  
During the tumor initiation and progression, DNA hypomethylation 
pattern was occurred in the cancer associated genes when comparing with 
normal tissues. Previously, the cancer-specific DNA methylation patterns 
was reported by comparing with associated tissues. The development of 
technologies in sequencing and microarray analysis are very supportive to 
examine and understand the aberrant epigenetic regulation specific to 
cancer.  
During differentiation, ESCs start in a pluripotent state from which 
they sequentially develop into unique cell type with a narrower 
pluripotency. Histone methylation is short-term silencing mechanism by 
which some set of genes required for development were repressed at the 
stage of stem cell [34,35]. On the other hand, DNA methylation are long-
term silencing mechanisms. Pluripotent stem cells express the set of 
transcription factors that are important for maintenance of stemness and 
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after development these genes are repressed by long-term silencing 
mechanisms. Therefore, in somatic cells the imprinted genes and 
pluripotency-associated genes were off by DNA hypermethylation [36,37]. 
The key developmental events with global epigenetic modifications and 
gene-expression patterns in mammalian cells were shown in Figure 1.2. 
 
Figure 1.2 Key developmental events with global epigenetic 
modifications and gene-expression patterns mammalian cells. [37] 
Some characteristics of CSC shared with normal stem cells 
including self-renewal and differentiation. Normal stem cells 
differentiated into the certain cell type in proper epigenetic regulation.  
Altered or aberrant epigenetic regulation was thought to be involved in 
CSC development required for the features of CSCs, highly proliferative, 
tumor formation, and metastatic ability to form the new tumor at distant 
site. The epigenetic regulation pattern for maintaining the stemness was 
occurred in CSC. The possibility of this evidence can be explained in two 
ways; one is dedifferentiation mechanisms gained in non-stem cancer cells 
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and another is the failure of DNA methylation mechanism in normal stem 
cell during differentiation.  
Several key developmental or signaling pathways have been shown 
to play essential roles to get the CSCs functions, especially tumorigenesis, 
cancer initiation and maintenance of self-renewing. Epigenetic 
deregulation may contribute the alteration in such kinds of pathways. 
Generally, the Jak-STAT, Wnt, Notch, Hedgehog, PI3K, and NF-kB 
signaling were shown to be involved in mediating various stem cell 
properties, such as self-renewal, cell fate decisions, survival, proliferation, 
and differentiation [38–40]. Recent reports interestingly had reported that 
the regulation of these signaling pathways are imbalanced in cancers. One 
of the reasons for these evidences could be the abnormal epigenetic 
regulations. Recently, the distinct DNA hypomethylation of specific gene 
sets in MCF7-derived mammosheres caused the activation of Jak-STAT 
pathway that was considered for the maintenance of CSC properties to be 
involved in the regulation of stem cells [38,41]. In gastric cancers, activation 
of Wnt pathways in were more frequently affected by epigenetic 
alterations than by genetic alterations in the related genes [42]. Moreover, 
it was reported that the activation of Hedgehog was related with epigenetic 
changes in which, Shh promoter hypomethylation was suggested as a 
critical event in breast carcinogenesis [43]. The Notch signaling pathway 
play important roles in developmental process, and cell-cell 
communication for regulating the cell proliferation, differentiation and cell 
lineage progression but it is also dysregulated in many cancers [44]. One 
of the growing evidences in epigenetic dysregulation of notch signaling 
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pathway showed that overexpression of Notch ligand has been gained 
from enhanced histone acetylation at promoter region of this ligand in 
multiple myeloma. 
In conclusion, although the experimental evidences of CSCs relating 
to their genetic and epigenetic regulation have been growing in number, 
the hypothesis of CSC still remain needed to understand how they develop, 
how different in characteristics depending on tissue, and dysregulation of 
key signaling pathways specific for their functions. It is very important to 
develop a CSC model that can sufficiently explain about the genetic or 
epigenetic profiles of CSC. The alteration mechanism in CSCs could be 
expected to be useful for development of specific therapy for cancer 
patients. 
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ABSTRACT 
Cancer stem cells (CSCs) are considered to be derived from normal stem 
cells affected by the tumor microenvironment through the genetic and epigenetic 
alterations that initiate malignant transformation. We have reported that the 
conditioned medium of Lewis lung carcinoma (LLC) cells can be used to convert 
mouse induced pluripotent stem cells (miPSCs) into cancer stem cell phenotype, 
which named miPS-LLCcm cells. miPS-LLCcm cells developed highly angiogenic 
and malignant adenocarcinoma after transplanted into nude mice. When miPS-
LLCcm cells were subcutaneously injected into a nude mouse, malignant 
adenocarcinoma-like tumor was formed with lung metastasis. 
Immunohistochemical analysis with GFP antibody showed that the nodules 
formed in lung expressed GFP, of which expression was controlled by Nanog 
promoter, further proving that these cells were metastatic to lung. This should 
therefore be a model to study lung metastasis from a tumor formed by 
subcutaneous injection. In this study, we analyzed the expression of three types 
of candidate genes for stem cell, tumor driver genes and epithelial–mesenchymal 
transition (EMT) on four different stages of cells. The CSC-like cells developed 
from miPSC exhibited self-renewal activity and stem cell marker gene expression. 
The expression of EMT markers were analyzed in the primary culture derived 
from the tumor and nodules metastasized to lung. The primary cells from the 
tumor highly expressed the EMT markers; snail, slug, Twist and N-cadherin. The 
results demonstrated in this study indicate that primary cells from tumor are rich 
in CSCs with high metastatic potential. 
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2.1. INTRODUCTION 
Tumors are composed of heterogeneous cancer cells with distinct 
morphological and functional profiles. This heterogeneity could be partially 
explained by the classical cancer initiation theory; evolutional accumulation of 
one or more mutations in a single or a few cells resulting in uncontrolled growth 
[1]. Another explanation is based on the presence of stem cells in tumors. Even in 
a few number the stem cells are considered to comprise the whole tumor in 
patient [2–4]. The heterogeneous population in cancer tissues are thought to be 
the progeny of stem cell population resulting from self-renewal and 
differentiation. Coupled with the malignant tumorigenic potential, the stem cells 
have been termed as cancer stem cells (CSCs) generating functionally hierarchical 
structure in a tumor. 
There is a considerable evidence that many different cancers have a unique 
subpopulation of self-renewing cells that can generate the diverse tumor cells. 
CSCs were identified in brain, breast, prostate, head and neck, pancreas, liver, 
ovary, and colon cancers, by using different markers, such as CD133, EpCAM, 
CD44, CD24, Lgr5 and ALDH1. The question about the origin of CSC is still 
controversial. The leukemic stem cells were the first identified with the cell-
surface markers, CD34+ CD38- differentiating in vivo into leukemic blasts [2]. This 
particular approach led to emerge new studies which described tissue-specific 
markers for solid tumors. The phenotype associated with cancers including 
motility, invasion and chemo-/radio-resistance could be traced to CSCs. 
Metastasis through the activation of CXCR4 receptor was previously 
demonstrated by the migration of invasive CSCs defined with CD133 in 
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pancreatic cancer [5]. On the other hand, other studies attributed their metastatic 
potential to the epithelial-mesenchymal transition (EMT) events showing that 
differentiated cancer cells could turn into CSC-like mesenchymal cells [6]. 
CSCs is normally characterized as fraction of cancer cells that have ability 
for self-renewal, pluripotency and sustaining of the bulk of cancer. The best 
evidence for the existence of CSCs was demonstrated with cancer stem cells 
model that is derived from mouse induced pluripotent stem cells (miPSC). When 
miPSC are cultured in the presence of conditioned medium prepared from 
various cancer cell lines, it acquires the characters of CSCs with high 
tumorigenicity and stemness. We have evaluated miPS-LLCcm cells that were 
derived from miPSCs developed in the conditioned medium of Lewis lung 
carcinoma (LLC) [7]. This cancer stem cell model has the highly tumorigenic and 
angiogenic ability and also metastatic potential was observed when spheroid cells 
were injected into the mouse tail vein, multiple metastatic nodules were found in 
lung after one month.  
Adult somatic cells have been successfully reprogrammed to pluripotent 
stem cells (iPSCs) with the transduction of four transcription factors [8]. The 
differentiation potential of iPSCs is largely expected to develop multiple potential 
avenues for the regenerative therapy. Immune rejection of embryonic stem cells 
can be avoided by replacing these with iPSCs. However, the risks of potential 
tumor development and other unpredictable biological changes during 
transplantation are still unresolved. The cellular interaction of transplanted cells 
in the microenvironment has been reported important to obtain successful results 
in regeneration therapy [9]. 
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In this evidence, our hypothesis is that miPSCs are affected by the 
conditioned medium to become the miPS-CSCs through the post-transcriptional 
and translational or epigenetic regulations. It is a good model to study the 
behaviors of CSCs in primary tumor induction and metastasis.  
 
2.2. RESULTS 
2.2.1. Conversion of miPSCs into CSC-like cells with tumorigenic and 
metastatic potential 
 We have reported a model of CSC-like cells converted from miPSC by the 
exposure to the conditioned medium (CM) from various cancer cell lines [7,10,11]. 
The miPSCs used in the studies had GFP under the control of Nanog promoter 
wherein undifferentiated stem cells exhibit strong GFP expression and 
differentiated cells lose green fluorescence. miPSCs were found to be viable in the 
presence of conditioned medium even when the differentiation was allowed 
while they started differentiation and failed to survive beyond 10 days without 
CM. This scheme is briefly summarized in Figure 2.1A. After 4 weeks of treatment 
with CM, the survived and undifferentiated cells expressing GFP were named as 
miPS-LLCcm cells. The self-renewal of miPS-LLCcm cells, a specific character of 
undifferentiated stem cells, was also confirmed by sphere-forming assay as well 
as its differentiation potential was evident with highly adhesive fibroblast-like 
phenotype and loss of GFP expression (Figure 2.1B).  
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(A)       (B) 
      
Figure 2.1. Conversion of miPSCs into miPS-LLCcm (A) Summarized 
scheme of conversion of miPSCs into miPS-LLCcm and its tumorigenic and 
metastatic activity. (B) Converted miPSCs in adherent culture (top) and in 
suspension culture (bottom). 
The subcutaneous transplantation of miPS-LLCcm cells into 
immunocompromised Balb/c nude mice generated malignant tumor together 
with the metastasized nodule-like structures in the lung (Figure 2.2A and 2.2B). 
These tumors and lung nodules were subjected to primary cell culturing to isolate 
GFP expressing cells. The primary cultured cells from tumors was named as Ptdc 
cells and the cells from lung nodules was named as LMN cells. The Ptdc cells were 
subsequently transplanted to generate the secondary tumor again. In the 
subcutaneous injection of 106 cells, the growth of tumors was compared (Figure 
2.2C). The Ptdc cells showed the most rapid growth when compared to miPS-
LLCcm cells and miPSCs.  
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Figure 2.2. Tumorigenic and metastatic potential of miPS-LLCcm (A) 
Tumors and metastatic nodules in lungs generated by subcutaneously 
transplanted miPSCs, miPS-LLCcm cells and Ptdc cells into the Balb/c-nu 
mouse. Arrows in lung indicate the positions of nodules. (B) The histogram 
showed the average number of lung nodules for each of the three cells. (C) 
The sizes of tumors growing in 4-6 weeks. 
Primary cultures derived from the tumors were positive for GFP signal, 
confirming they were originated from miPS-LLCcm cells and not from host cells, 
and displayed sphere-forming activity suggesting they preserve stem-like 
characteristics (Figure 2.3A and 2.3B). miPS-LLCcm cells, Ptdc cells and LMN 
cells maintained the expression of endogeneous stemness markers, such as 
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Nanog, Oct3/4, Sox2 and Klf4 without LIF similar with the untreated miPSCs 
cultured in the presence of LIF (Figure 2.4). Therefore, the stemness can be 
maintained in the presence of CM and this conversion supports the establishment 
of CSC-like features. 
 
Figure 2.3. Primary cultured cells (A) Ptdc cells in adherent culture (top) and 
sphere formation in suspension culture (bottom) with the expression of GFP. 
(B) LMN cells in adherent culture (top) and sphere formation in suspension 
culture (bottom) with the expression of GFP. 
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Figure 2.4. Comparison of the expression levels of stemness markers by rt-
qPCR. a, miPSCs; b, miPS-LLCcm cells; c, Ptdc cells; d, LMN cells. 
Histological analysis of the tumor showed poorly differentiated phenotype, 
high nuclear to cytoplasmic ratio, micrometastasis and some epithelial ductal-like 
structure, which are the signs of malignancy (Figure 2.5A). Metastatic node-like 
structures were observed in the lung of the mice (Figure 2.5B). Untreated miPSCs 
tumor displayed teratoma like phenotype with various germ layers (Figure 2.5C). 
These observations confirmed the self-renewing and tumorigenic potential of 
miPS-LLCcm cells.  
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Figure 2.5. Histological analyses of allografts of miPS-LLCcm cells. (A) High 
nuclear to cytoplasmic ratio (a) and with the mass of undifferentiated cells 
(asterisks in (b)), granular epithelial structure (arrows in (c)) and 
micrometastasis (arrows in (d)). (B) Metastatic nodules-like tumor in the 
lung pulmonary tissue (left), in the lung tissue (middle), and in the chest 
(right). (C) Teratoma from untreated miPSCs showing the three germ layers: 
squamous epithelial tissue (asterisks) in ectoderm (left), muscle tissue in 
mesoderm (middle) and gland-like structures (asterisks) in endoderm 
(right). (A-C) H&E staining. 
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2.2.2. Characterization of miPS-LLCcm, Ptdc and LMN cells 
In order to further confirm the acquisition of CSC-like phenotype, we 
assessed the expression of the commonly known CSC markers, CD44 and ALDH1 
by rt-qPCR as well as immuno-histochemical analysis. (Figure 2.6A and 2.6B). The 
LMN and Ptdc cells showed the significantly higher expression of ALHD1 and 
CD44 than the miPSCs. The miPS-LLCcm derived tumor also showed the 
expression of these two markers.  
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Figure 2.6. The localization and expression of CSC markers. (A) IHC analysis 
showing the expression of CD44 and ALDH1 in the tumor of the miPS-
LLCcm cells. (B) The comparison of the expression of CD44 and ALDH1 the 
Ptdc and LMN cells with miPS-LLCcm by rt-qPCR analysis. ***P < .001, **P 
< .01, *P < .05. 
2.2.3. In vivo tumorigenic differentiation of miPS-LLCcm  
 MUC1 plays a crucial role in cancer progression and is considered as a 
suitable marker for the adenocarcinoma tumor phenotype [12]. Immuno-
histochemical analysis showed that tumor associated MUC1 expression was 
detected in tumor of miPS-LLCcm (Figure 2.7A). Mass of highly proliferating cells 
showed the expression of GFP as population of cells that are maintaining self-
renewal ability.  
 Ptdc cells showed the upregulation of both E-cadherin, an epithelial marker, 
and N-cadherin, a mesenchymal marker, as compared to miPS-LLCcm and LMN 
cells (Figure 2.7B and 2.7C). The expression of Snail, Slug, Twist1 and Twist2 were 
also upregulated in Ptdc cells suggesting the potential of epithelial-to-
mesenchymal transition (EMT) in Ptdc cells. 
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Figure 2.7. The localization and expression of EMT markers in miPS-LLCcm 
derived tumors. (A) Immuno-histochemical (IHC) analysis showed that 
ductal epithelial structure expressed MUC1 (left) and the undifferentiated 
mass of cells expressed the GFP (right). Comparison of the expression of (B) 
epithelial and mesenchymal markers (E-cadherin and N-cadherin) and (C) 
EMT markers in a, miPS-LLCcm cells; b, Ptdc cells and c, LMN cells. 
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2.3. MATERIALS AND METHODS 
2.3.1. Cell Culture 
Mouse Lewis Lung Carcinoma cell lines (LLC) were purchased from ATCC 
(USA) and maintained in DMEM (D5796 Sigma) medium containing 10% fetal 
bovine serum (FBS,Gibco,NY) and 100 U/ml penicillin/streptomycin 
(Wako,Japan). Mouse induced pluripotent stem cells (miPS, iPS-MEF-Ng-20D-17; 
Lot No.012, Fiken Cell Bank, Japan) were cultured in DMEM containing 15% FBS, 
0.1 mM NEAA (100X NEAA, Gibco, NY), 2mM L-Glutamine (Nacalai Tesque, 
Japan), 50U/ml of penicillin/streptomycin (P/S), 0.1 mM 2-mercaptoethanol 
(Sigma) and 1000 U/ml of Leukemia Inhibitory Factor (LIF, Millipore, MA) on 
feeder layers of mitomycin treated mouse embryonic fibroblast (MEF) cells 
(Reprocell, Japan). In the case of feeder-less, the miPS cells were cultured on 
gelation (0.1%) coated dishes. The expression of GFP and cell morphology was 
observed and photographed using Olympus IX81 microscope equipped with a 
light fluorescence device (Olympus, Japan).  
2.3.2. Conversion of miPSCs into the CSC-like cells 
According to the methods reported by Chen L and Kasai T et al., we cultured 
the miPSCs in the presence of conditioned medium of LLC cells [7]. Nanog-GFP 
reporter expression was used in miPSC cells and the expression of GFP reflects 
the maintenance of stemness [13]. LLC cells were cultured and prior to collecting 
conditioned medium, the cells were changed into 5% serum medium at 70-80% 
confluency. After 48hrs incubation, the conditioned medium (CM) from LLC cells 
was collected and filtered through a 0.22 µm filter (Millipore, Ireland). The 
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miPSCs were treated with the CM for 4 weeks and miPSCs were cultured in the 
presence or absence of LIF as controls. The miPSCs cultured under feeder-less 
conditions were treated with the CM in 1:1 ratio of miPS medium and CM for four 
weeks. 
2.3.3. Sphere Formation Assay  
To generate the spheroids, serum free medium (DMEM 97.5%, NEAA 1%, 
L-Glutamine 1%, 100X Pen/Strep 0.5%, 0.1 mM 2-mercaptoethanol, and Insulin-
transferrin-selenium-X 1/100 v/v (ITS-X, life technologies, CA) was used and 
single cells were plated on ultra-low attachment dishes (Corning incorporated, 
NY) at cell density of 1x104 cells/ml [14]. 
2.3.4. Animal experiments 
The plan of animal experiments was reviewed and approved by the ethics 
committee for animal experiments of Okayama University under the IDs OKU-
2013252, OKU-2014157, OKU-2014429 and OKU-2016078. All experiments were 
performed according to the Policy on the Care and Use of the Laboratory Animals, 
Okayama University. Nude mice (Balb/c-nu/nu, female, 4 weeks) were 
purchased CharlesRiver, Japan. Cells at 1x106 were suspended in 200 !l of HBSS 
(Hanks Balanced salt solution, Gibco, NY) and were subcutaneously transplanted 
into nude mice. 
2.3.5. Preparation of primary cell culture 
To prepare the primary culture from a mouse allograft, the tumor was 
excised and cut into small pieces (approximately 1 mm3) and washed in the 
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Hank’s buffered salt solution (HBSS) for three times. These pieces were 
transferred into a 15-ml tube with 4 ml of dissociation buffer prepared in PBS 
containing 0.25% trypsin, 0.1% collagenase, 20% KnockOut™ Serum Replacement 
(Gibco, NY), 1 mM of CaCl2 and incubated at 37°C for 40 mins. To terminate the 
digestion, 5 ml of DMEM containing 10% FBS was then added. The cellular 
suspension transferred into the new tubes and centrifuged at 1000 rpm for 5 mins. 
The cell pellet was suspended in 5 ml of HBSS, and centrifuged at 1000 rpm for 5 
min. The cell pellet was placed into an appropriate volume of miPS medium 
without LIF and the cell number was counted with hemocytometer. Then the cells 
at 5×105 were seeded per 60-mm dish. After a passage, the cells derived from 
mouse allografts were cultured in the presence of 1 !g/mL of puromycin for 24 
hours to remove the host derived cells.  
To prepare the primary culture from metastatic nodules in a lung, the lung 
tissue was excised and cut into small pieces (approximately 1 mm3) and washed 
in the HBSS for three times. And the same procedures with those for the cells from 
a tumor allograft were employed to prepare the cells.  Finally, the expression of 
GFP and cell morphology was observed and photographed using Olympus IX81 
microscope equipped with a light fluorescence device (Olympus, Japan).  
2.3.6. RNA extraction, cDNA synthesis and qPCR mRNA expression analysis 
Total RNA was extracted using RNAeasy Mini kit (QUIAGEN, Germany) 
according to the manufacturer's instructions and 1 !g of RNA was reverse 
transcribed using Superscript First strand kit (Invitrogen, CA). Quantitative real 
time PCR was performed with cycler 480 SYBR green I Master Mix (Roche, 
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Switzerland) according to manufacturer’s instructions. Primers used for qPCR are 
listed in Table 2.1. 
Table 2.1. List of Primers Used in the Experiments 
No Names Forward Primer Sequence Reverse Primer Sequence 
1 Nanog AGGGTCTGCTACTGAGATGCTCTG AACCCAAGCACGTATCAGGG 
2 Oct3/4 TCTTTCCACCAGGCCCCCGGCTC TGCGGGCGGACATGGGGAGATCC 
3 Sox2 TAGAGCTAGACTCCGGGCGATGA TTGCCTTAAACAAGACCACGAAA 
4 Klf4 GGACTTACAAAATGCCAAGGGGTG TCGCTTCCTCTTCCTCCGACACA 
5 CD44 AGAAAAATGGCCGCTACAGTATC TGCATGTTTCAAAACCCTTGC 
6 ALDH1 AACACAGGTTGGCAAGTTAATCA TGCGACACAACATTGGCCTT 
7 E-cadherin AACCCAAGCACGTATCAGGG GGGGTCTGTGACAACAACGA 
8 N-cadherin CCTTGCTTCAGGCGTCTGTG CTTGAAATCTGCTGGCTCGC 
9 Snail GGAGTTGACTACCGACCTTGC TGGAAGGTGAACTCCACACAC 
10 Slug GCCCTTAAAGGCACTAACGAG ATTCACGAAGGTGACGAGCC 
11 Twist1 GCCGGAGACCTAGATGTCATTGT TTAAAAGTGTGCCCCACGCC 
12 Twist2 CTCACGAGCGTCTCAGCTAC TTGTCCAGGTGCCGAAAGTC 
13 GADPH AACGGCACAGTCAAGGCCGA ACCCTTTTGGCTCCACCCTT 
 
2.3.7. Histological analysis and immunohistochemistry (IHC) 
Paraffin embedded tumor sections (5!m) were stained with Hematoxylin 
(Sigma Aldrich,USA ;0.5%) and Eosin Y (Sigma Aldrich, USA) (HE) for 
histological analysis. Primary antibodies and dilutions used for IHC were used as 
follows; anti-GFP antibody 1:200 (#2956, Cell Signaling, USA), anti-MUC1 
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antibody 1:100 (Abcam/ab15481, UK), anti-ALDH1 antibody 1:200 (Abcam/ 
ab52492, UK) and Anti-CD44 antibody 1:200 (Abcam/ ab24504, UK). 
2.3.8. Statistical analysis 
The data were analyzed using two-tailed student’s t-test and are presented 
as the mean ± standard deviation (SD) at least three-time determinations. A P-
values less than 0.05 was considered to be statically significant, while less than 
0.01 was highly significant. 
 
2.4. DISCUSSION 
The current study focused on the DNA methylation in the CSC model 
converted from iPSCs by the treatment with conditioned medium of cancer cells. 
By the treatment, miPSCs obtained the ability of unlimited growth and the 
capacity to maintain their stemness, while they were allowed to differentiate 
without LIF. The subcutaneous transplantation of the survived cells into the 
mouse formed malignant tumors and metastasized into lung tissues. Thus, we 
concluded that miPSCs should be converted into CSCs without any intended 
genetic manipulation. The immunohistochemical analysis revealed the 
heterogeneity of the tumors, in which miPS-LLCcm cells should on one hand 
maintain the undifferentiated population expressing GFP and differentiate on the 
other into adenocarcinoma phenotype expressing MUC1 while miPSCs 
developed benign teratoma showing the three germ-layers differentiation and the 
loss of undifferentiated phenotype. Furthermore, the cells from benign teratoma 
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cannot be maintained but the cells from tumors at primary site and metastatic 
nodules can be maintained in vitro.  
The heterogeneous phenotypes characterized by the expression of E-
cadherin and N-cadherin in the Ptdc cells should be implying the progression of 
cancer and metastatic potential of the tumor maintaining the plasticity of the 
transition between epithelial and mesenchymal states. Further study is required 
to confirm the cells are undergoing the EMT being involved in maintenance of 
stemness, invasiveness and metastasis of tumor cells. 
Recently our group generated CSC models converted from iPSCs with the 
aid of CM of various cancer cell lines such as human pancreatic carcinoma cell 
lines PK-8 cells and KLM-1 cells, human breast cancer cell lines T47D cells and 
BT549 cells, mouse carcinoma cell lines LLC cells, P19 cells, B16 cells and MC.E12 
cells [7,10,11]. In the conversion of pancreatic duct like adenocarcinoma (PDAC) 
like CSC model, there was no evidence relating to single point mutations even in 
Kras oncogene and its xenografts tumors showed the features of acinoductal 
metaplasia, pancreatic intraepithelial neoplasia and PDAC lesions[10]. We 
postulated that CSCs may be induced epigenetic changes without any known 
mutations. 
Premature termination of reprogramming were reported to result in tumor 
development in various tissues with undifferentiated dysplastic cells exhibiting 
global changes in DNA methylation at H19 DMRs identifying IGF-2 expression 
up-regulated in the tumor initiating cells [31]. Since the changes in DNA 
methylation was considered responsible for the conversion of iPSCs into CSCs, 
the patterns of DNA methylation were compared between the converted cells 
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(miPS-LLCcm cells), tumor derived cells (Ptdc cells and LMN cells) and miPSCs. 
As the results of bisulfite sequencing, we evaluated the list of epigenetically 
affected genes regarding to the DMRs in the miPS-LLCcm cells and Ptdc cells and 
LMN cells. Hypo- and hypermethylated genes were identified and 
hypomethylation was found overall superior to hypermethylation in all CSCs 
when compared to the parental cell line miPSCs. 
The analysis of KEGG pathways relating to hypomethylated genes revealed 
the several notable pathways important in cancers. Checking the expression of 
genes associated with these pathways, the expression of hypomethylated genes 
relating to PI3K-Akt pathway was found significantly high among those of the 
other genes. PI3K-Akt-mTOR signaling pathway has previously been reported as 
a key driver of carcinogenesis in several cancer types [32,33]. In this study, we 
found Pik3r5 (p101), which is a regulatory subunit of Pik3cg enzyme, as a 
hypomethylated and highly up-regulated gene relating to PI3K-Akt pathway. In 
the recent report, the evidence of PIK3CG as a potential oncogene were evaluated 
by analyzing the differential role each unit of PIK3CG, of which overexpression 
of the catalytic subunit PIK3CG (p110γ) or the regulatory subunit PIK3R5 (p101) 
leads to oncogenic cellular transformation and malignancy [34]. Therefore, the 
hypomethylation of Pik3r5 gene leading to the up-regulation is closely related to 
the activation/phosphorylation of AKT that is the downstream target molecule 
and Pik3cg should play a key role in carcinogenesis. In fact, the multiple myeloma 
cells derived from patients, the upregulation of PI3K components, in which 
PIK3CG has been proved to be a main regulator of cells adhesion and migration 
[35]. The PIK3CA gene has been reported to be hypomethylated in esophageal 
cancer cases when compared to the adjacent normal tissues [36]. On the other 
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hand, both Pik3r5 and Pik3cg were overexpressed resulting in the up-regulation 
of PI3K-gamma in the class IB PI3Ks, but not the PI3K-alpha in the class IA in our 
CSCs. Collectively, the activation of PI3K-Akt signaling pathway should 
significantly be relating with the conversion of miPSC into miPS-LLCcm cells 
resulting in the constitutive activation of Akt in Ptdc and LMN cells. 
According to the recent reports, the tumor cells produced a variety of 
molecules such as growth factors, cytokines and chemokines, which exhibited 
various effects such as on tumor growth and angiogenesis, providing them with 
various microenvironments [37,38]. In our study, we have successfully 
demonstrated the CSCs generated from iPSCs by the treatment with CM from 
cancer derived cells acquired the DNA hypomethylation.  
 
2.5. CONCLUSIONS 
Significant overall DNA hypomethylation during the conversion should 
lead to the activation of certain proto-oncogene, which represent the malignant 
conversion even without mutations. In this context, the hypomethylation might 
be considered to contribute to the progression and metastasis of the cancer stem 
cells. 
 
 
 
CHAPTER 2 
 
45 
REFERENCES 
1.  Rozhok, A. I.; Salstrom, J. L.; DeGregori, J. Stochastic modeling indicates 
that aging and somatic evolution in the hematopoietic system are driven 
by non-cell-autonomous processes. Aging (Albany. NY). 2014, 6, 1033–1048, 
doi:10.18632/aging.100707. 
2.  Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 
1997, 3, 730–737, doi:10.1038/nm0797-730. 
3.  Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. No Title. Nature 
2001, 414, 105–111, doi:10.1038/35102167. 
4.  Clarke, M. F.; Dick, J. E.; Dirks, P. B.; Eaves, C. J.; Jamieson, C. H. M.; 
Jones, D. L.; Visvader, J.; Weissman, I. L.; Wahl, G. M. Cancer Stem Cells—
Perspectives on Current Status and Future Directions: AACR Workshop 
on Cancer Stem Cells. Cancer Res. 2006, 66, 9339–9344, doi:10.1158/0008-
5472.CAN-06-3126. 
5.  Hermann, P. C.; Huber, S. L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, 
M.; Bruns, C. J.; Heeschen, C. Distinct Populations of Cancer Stem Cells 
Determine Tumor Growth and Metastatic Activity in Human Pancreatic 
Cancer. Cell Stem Cell 2007, 1, 313–323, doi:10.1016/j.stem.2007.06.002. 
6.  Sampieri, K.; Fodde, R. Cancer stem cells and metastasis. Semin. Cancer 
Biol. 2012, 22, 187–193, doi:10.1016/j.semcancer.2012.03.002. 
7.  Chen, L.; Kasai, T.; Li, Y.; Sugii, Y.; Jin, G.; Okada, M.; Vaidyanath, A.; 
CHAPTER 2 
 
46 
Mizutani, A.; Satoh, A.; Kudoh, T.; Hendrix, M. J. C.; Salomon, D. S.; Fu, 
L.; Seno, M. A model of cancer stem cells derived from mouse induced 
pluripotent stem cells. PLoS One 2012, 7, 
doi:10.1371/journal.pone.0033544. 
8.  Takahashi, K.; Yamanaka, S. Induction of Pluripotent Stem Cells from 
Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 
2006, 126, 663–676, doi:10.1016/j.cell.2006.07.024. 
9.  Wan, P.-X. Importance of the stem cell microenvironment for 
ophthalmological cell-based therapy. World J. Stem Cells 2015, 7, 448, 
doi:10.4252/wjsc.v7.i2.448. 
10.  Calle, A. S.; Nair, N.; Oo, A. K.; Prieto-Vila, M.; Koga, M.; Khayrani, A. C.; 
Hussein, M.; Hurley, L.; Vaidyanath, A.; Seno, A.; Iwasaki, Y.; Calle, M.; 
Kasai, T.; Seno, M. A new PDAC mouse model originated from iPSCs-
converted pancreatic cancer stem cells (CSCcm). Am. J. Cancer Res. 2016, 6, 
2799–2815. 
11.  Nair, N.; Calle, A. S.; Zahra, M. H.; Prieto-Vila, M.; Oo, A. K. K.; Hurley, 
L.; Vaidyanath, A.; Seno, A.; Masuda, J.; Iwasaki, Y.; Tanaka, H.; Kasai, T.; 
Seno, M. A cancer stem cell model as the point of origin of cancer-
associated fibroblasts in tumor microenvironment. Sci. Rep. 2017, 7, 6838, 
doi:10.1038/s41598-017-07144-5. 
12.  Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role 
in cancer progression. Trends Mol. Med. 2014, 20, 332–342. 
CHAPTER 2 
 
47 
13.  Okita, K.; Ichisaka, T.; Yamanaka, S. Generation of germline-competent 
induced pluripotent stem cells. Nature 2007, 448, 313–317, 
doi:10.1038/nature05934. 
14.  Dontu, G.; Abdallah, W. M.; Foley, J. M.; Jackson, K. W.; Clarke, M. F.; 
Kawamura, M. J.; Wicha, M. S. In vitro propagation and transcriptional 
profiling of human mammary stem / progenitor cells. Genes Dev. 2003, 17, 
1253–1270, doi:10.1101/gad.1061803.potential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER (3) 
“Up-Regulation of PI 3-Kinases and the 
Activation of PI3K-Akt Signaling Pathway in 
Cancer Stem-Like Cells Through DNA 
Hypomethylation Mediated by the Cancer 
Microenvironment” 
 
 
 
 
 
 
 
CHAPTER 3 
 
50 
ABSTRACT 
The tumors formed by subcutaneous injection of miPS-LLCcm cells that 
were converted from miPSCs, showed the structures with pathophysiological 
features consisting of undifferentiated and malignant phenotypes generally 
found in adenocarcinoma. Metastasis in the lung was also observed as nodule 
structures. Excising from the tumors, primary cultured cells from the tumor and 
the nodule showed self-renewal, differentiation potential as well as tumor 
forming ability, which are the essential characters of CSCs. Since this conversion 
is triggered only by the factor(s) contained in the conditioned medium, we have 
hypothesized that miPSCs are induced to cancer stem cells (CSCs) through 
epigenetic regulations without genetic modifications. We then characterized the 
epigenetic regulation occurring in the CSCs. By comparing the DNA methylation 
level of CG rich regions, the differentially methylated regions (DMRs) were 
evaluated in all stages of CSCs when compared with the parental iPSCs. In DMRs, 
hypomethylation was found superior to hypermethylation in the miPS-LLCcm 
cells and its derivatives. The hypo- and hypermethylated genes were used to 
nominate KEGG pathways related with CSC. As a result, several categories were 
defined in the KEGG pathways from which most related with cancers, significant 
and high expression of components was PI3K-AKT signaling pathway. 
Simultaneously, the AKT activation was also confirmed in the CSCs. The PI3K-
Akt signaling pathway should be an important pathway for the CSCs established 
by the treatment with conditioned medium of LLC cells. 
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3.1. INTRODUCTION 
Genetic mutation in tumor suppressors and oncogenic drivers have been 
widely described in the subsets of cancer patients. Mutation hypothesis is not only 
the sole reason of malignancy but also the epigenetic abnormalities have been 
involved in the tumorigenesis.  Without changing in DNA sequence, the ability 
to change the expression of genes is the primary role of epigenetic regulation. 
Recent reports determined that epigenetic mechanisms, such as DNA 
methylation, can be involved in stem-cell maintenance and in the regulation of 
differentiation of stem cells [1,2]. Transcriptional silencing of tumor suppressor 
genes by promoter DNA hypermethylation is frequently found in human 
carcinogenesis [3]. However, hypomethylation was thought to be the epigenetic 
changes found in the early stages of carcinogenesis. Hepatocellular carcinoma 
lines that had been transformed with chemical carcinogens showed an aberrant 
hypomethylation of endogenous DNA during neoplastic transformation [4]. The 
global methylation difference between normal tissues and tumors showed that 
overall global hypomethylation is involved in oncogenesis or tumor progression 
[5]. 
It is well known that DNA methylation is one of the epigenetic 
modifications of DNA in all unicellular and multicellular organisms, associated 
with cell differentiation and proliferation [6]. Differentially methylated regions 
(DMRs) are stretches of DNA in the genome at which multiple adjacent CpG sites 
show differential methylation when comparing between two samples [7]. 
Growing evidences have shown that in many cancers, global DNA methylation 
changes contribute to alter gene expression programs, genomic instability, and 
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facilitate genetic mutations [8–10]. Most of researches in DNA methylation 
analyses have focused on aberrant methylation at the promoter, CpG rich and 
enhancer regions of related genes [11]. 
Recently, we demonstrated that the microenvironment of cancer cells can 
affect stem cells to convert iPSCs into CSC-like cells, with tumorigenic capacity as 
well as self-renewal and differentiation potential. In the present study, we tried 
to prove our hypothesis that epigenetic alterations can induce CSCs from normal 
stem cells in the tumor microenvironment. 
3.2. RESULTS 
3.2.1. Global DNA methylation analysis in Cancer Stem-like Cells  
We analyzed the global DNA methylation status of miPS-LLCcm and its 
derivatives and used miPSC as control. After filtering low quality reads from raw 
RRBS sequencing data, we generated 4.9, 4.3, 3.9, 3.7 clean Gb of paired-end 
sequence data of miPSC, miPS-LLCcm, Ptdc, and LMN cells respectively [Table 
S1]. After filtering, clean reads were mapped to the reference sequence using 
BSMAP and the genome. From the clean reads 4.9, 4.3, 3.9, 3.7 Gb, uniquely 
mapping rate (77.15%, 74.82%, 75.9% and 77.79% respectively) were successfully 
aligned to the reference genome (mm10, GRC38 mouse), providing an average 
12.02X, 11.7X, 8.9X, and 8.58X sequencing depth. The coverage of sequencing in 
all samples were 68.707%, 68.176%, and 663.969% and 62.886% of whole genome. 
The quality control items of sequencing data are corresponding to Table S2. 
According to the sequence context of cytosine in the DNA sequence, it can 
be classified into three types, CG, CHG and CHH (H=A, G, or T). The decreasing 
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line in Figure S1 reveled the range of effective sequencing depth of cytosine. 
These RRBS products cover the most number of promoters and CpG island of 
target regions, here we list the covered information include total number in 
genome, theoretical value in target region and the actual value which are covered 
by at least 5 CGs [Table 3.1] [Figure S2]. 
Table 3.1. Covered Promoter and CGI number of target regions 
 
 
 
 
The coverage of methyl-cytosines were occurred in two featured regions; 
promoter and CpG island, the data for proportion of total methyl-cytosine was 
shown in Table S3. Among the methylated cytosine contexts, percentage of CG 
methylation pattern support the enough coverage. In the case of the proportions 
of methyl-cytosine pattern, mCG was the most common in both regions of all 
samples. Average Methylation level of each sample is shown in Table S4 and 
determined by the reads which covered in cytosine, it was also equal the mC/C 
ratio at each reference cytosine. Methylation status of CG, CHG and CHH differ 
among species and even varies with different conditions concerning time, space 
and physiology within a single organism. The distribution of methyl-cytosine was 
analyzed according to methylation level, demonstrating that the different 
patterns were observed in four different stages of CSC model [Figure S3]. 
 PROMOTER CGI 
Whole Genome 24,445 16,023 
Target Region 13,287 14,198 
miPSC 9,368 11,719 
miPSC_LLCcm 9,410 11,949 
Ptdc cells 4,938 7,277 
LMN Cells 5,181 7,687 
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3.2.2.  Analysis of the differentially methylated regions (DMRs) in the cancer 
stem cell model converted from iPSCs 
Epigenetic alterations have been attributed to play an important role in 
carcinogenesis. Methylation and demethylation is generally considered to silence 
and activate gene expression, respectively. However, the epigenetic changes in 
early stages of cancer development in this research has not yet been assessed. 
Since the 4-week treatment of iPSCs with LLC-CM appears to be the main source 
of conferring the potential of CSCs to generate miPS-LLCcm, we hypothesized 
that altered epigenetic regulation rather than gene mutations, may perform an 
essential role in this conversion process. Sliding-window approach identified 
differentially methylated regions (DMRs), which contains at least five CG sites. 
The methylation levels were significantly different between the samples when 
assessed by Fisher test (P <0.05). 
We compared the methylation in miPS-LLCcm, LMN and Ptdc cells with 
that in miPSC by three sets; (1) miPSCs vs. miPS-LLCcm cells, (2) miPSCs vs. Ptdc 
cells and (3) miPSCs vs. LMN cells. From these three comparisons, 926, 583 and 
1105 DMRs were identified respectively (Figure 3.1A-3.1C and Table 3.2). All 
DMRs between the different cell populations were found to exhibit 
hypomethylation as compared to miPSCs (Figure 3.2). 
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(A) 
      
(B) 
    
(C) 
    
 
Figure 3.1. DMR in each chromosome and methylation pattern changes 
(Hyper and Hypomethylated DMRs) (A) miPSCs Vs miPS-LLCcm cells (B) 
miPSCs Vs Ptdc cells (C) miPSCs Vs LMN cells. 
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Table 3.2. Number and length of DMRs in each comparison with distribution 
in each chromosome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Relative DNA methylation levels of DMRs when miPS-LLCcm 
cells, Ptdc cells and LMN clells compared to miPSCs. miPSCs vs miPS-
LLCcm cells (left), miPSCs vs Ptdc cells (middle) and miPSCs vs LMN cells 
(right).  
#Chr 
miPSCs Vs miPS-
LLCcm cells 
miPSCs Vs Ptdc 
cells 
miPSCs Vs LMN 
cells 
DMR 
number 
DMR 
length 
DMR 
number 
DMR 
length 
DMR 
number 
DMR 
length 
chr1 90 22576 51 14197 83 23430 
chr2 57 15754 43 12381 79 22178 
chr3 49 12193 17 4575 32 8717 
chr4 58 14374 39 10165 86 23431 
chr5 66 17269 48 11344 75 21109 
chr6 38 9749 29 8886 35 10530 
chr7 76 18897 50 14132 85 23809 
chr8 73 18255 31 8643 86 23922 
chr9 45 11617 20 5377 45 12762 
chr10 37 10686 32 7642 55 14107 
chr11 84 22756 54 14689 115 33193 
chr12 31 8340 20 4956 32 8975 
chr13 26 7471 24 7108 41 11191 
chr14 24 5650 16 4445 35 8621 
chr15 46 11328 20 5208 52 13480 
chr16 26 6278 19 4440 35 8311 
chr17 47 11768 20 6246 47 14115 
chr18 18 4935 16 4820 31 9282 
chr19 20 5025 21 6078 35 10283 
chrX 15 3763 9 2505 16 4616 
chrY 0 0 4 734 5 1253 
chrM 0 0 0 0 0 0 
Total 926 238684 583 158571 1105 307315 
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DMRs-associated genes were further identified and segregated into hypo- 
and hyper-methylated genes categories (Dataset S2A,B, S3A,B, S4A,B). To 
validate whether the genes with DMRs were enriched for certain pathways, we 
performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis 
for the hypomethylated genes in miPS-LLCcm, Ptdc and LMN cells. According 
the numbers of hypomethylated genes involved in the pathway, the top 15 KEGG 
pathways were nominated (Figure 3.3A and 3.3C and Table S5-S7) (Dataset S2C, 
S3C, S4C). We then selected the pathways most relevant for carcinogenesis 
including Focal adhesion, PI3K-Akt signaling pathway, Calcium signaling 
pathway, Pathway in cancer and Transcriptional misregulation in cancer. 
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Figure 3.3. KEGG pathways nominated with the number of hypomethylated 
genes (A) miPSCs vs. miPS-LLCcm cells, (B) miPSCs vs. Ptdc cells (C) 
miPSCs vs. LMN cells. 
 
3.2.3. Overexpression of PI3K-Gamma Candidates in the Model were Relating 
to Oncogenic Potential 
To evaluate the up-regulated expression of the hypomethylated genes in 
the pathway selected above, we performed rt-qPCR analysis on the miPS-LLCcm 
cells together with the Ptdc and LMN cells. As the results, the expression of 11 
genes were found up-regulated in miPS-LLCcm cells when compared to miPSCs 
(Figure 3.4). Among the candidates, Pik3r5 (p101) showed significantly high 
expression in all the cells. Recent reports have suggested that the overexpression 
of the catalytic subunit Pik3cg (p110γ) or the regulatory subunit Pik3r5 leads to 
oncogenic cellular transformation and malignancy [12]. These two subunits are 
class IB PI3Ks and considered to make a heterodimer of PI3K-gamma. We 
assessed the expression levels of Pik3cg and Pik3ca, which were class IB and class 
IA PI3Ks, in the miPS-LLCcm, Ptdc and LMN cells. As the result, Pik3cg showed 
significantly higher expression (P <0.01) than that of Pik3ca (Figure 3.5A). 
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Figure 3.4. Expression of hypomethylated genes significant in KEGG-
pathway related to cancer. rt-qPCR analyses of the candidate 
hypomethylated genes. 
3.2.4. PI3K-Akt Activation Drives iPSC-CSCs Model 
The up-regulated expression of Pik3r5 should induce the activation of Akt 
resulting in the onset of tumorigenicity and metastatic potential of miPS-LLCcm 
cells and Ptdc cells. Based on the evaluation in rt-qPCR, the constitutive 
expression of Pik3r5 was detected by immunoblotting with anti-p101 antibody in 
miPS-LLCcm and its derivatives (Figure 3.5B). Akt activation was simultaneously 
assessed by Western blotting with anti-phosphorylated Akt (p-Akt) antibody. We 
found Akt was constitutively activated in miPS-LLCcm, Ptdc and LMN cells 
(Figure 3.5B). In miPSCs, Akt was weakly activated in the presence of LIF but not 
in the absence of LIF. Taking these into consideration, the hypomethylation 
should lead to overexpress PI3K-gamma to enhance PI3K-Akt pathway in CSC-
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like cells without mutations in the open reading frames of DNA (Figure S4). These 
findings are consistent with the PI3K-Akt pathway as recognized one of the most 
frequent signaling pathway enhanced in human cancers [13]. 
 
Figure 3.5. Evaluation of the candidate signaling pathway nominated by 
the KEGG analysis. (A) rt-qPCR analyses of Pik3cg (top) and Pik3ca 
(bottom); ***P < .001, **P < .01, *P < .05. (a, miPSCs; b, miPS-LLCcm cells; c, 
Ptdc cells; d, LMN cells). (B) Immunoblotting analysis of AKT activation 
and the expression of Pik3r5.  
 
3.3. MATERIALS AND METHODS 
3.3.1. RRBS DNA methylation analysis 
The RRBS methylation analysis was performed by the BGI sequencing 
company. Extraction of DNA was carried out by QIAamp DNA Mini Kit 
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(QUIAGEN, Germany) according to manufacturing protocol. For RRBS library 
constructing, the DNA samples were digested with restriction enzyme after 
checking the sample quality test. This is followed by DNA-end repair, 3'-dA 
tailing, adapter ligation and size selection were carried out for fragments between 
40 and 220 bps in length. Finally, bisulfite treatment was carried out with ZYMO 
EZ DNA Methylation-Gold kit (Zymo Research, USA) and converted fragments 
were amplified by PCR and the prepared RRBS library were further sequenced 
for the analysis.  
RRBS libraries were sequenced on Illumina HiSeq 4000 using the PE100 
sequencing strategy. Data filtering was performed to remove adaptor sequences, 
contamination and low-quality reads. The low-quality reads mean that the ratio 
of unknown base (N) is over 10 % and the ratio of quality less than 20 bases over 
10%. After filtering the remaining reads are called clean reads and stored as 
FASTQ format. The clean reads were mapped to the reference sequence (mm10) 
using BSMAP in which the mapping rate and bisulfite conversion rate of each 
sample is calculated [14].  
Methylation level (!") is determined by the reads which covered in cytosine, 
it was also equal the mC/C ratio of each reference cytosine [15,16]. The formula 
was as following; 
!" = $"$" + $&" ∗ 100 
($" represents the reads number of mC, while $&" represents the reads number 
of non-methylation reads.) 
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Putative DMRs were identified by comparison of the sample1 and sample 2 
methylomes using windows that contained at least 5 CpG (CHG or CHH) sites 
with a 2-fold change in methylation level and Fisher test pvalue<0.05. Two nearby 
DMRs would be considered interdependent and joined into one continuous DMR 
if the genomic region from the start of an upstream DMR to the end of a 
downstream DMR also had 2-fold methylation level differences between sample 
1 and sample 2 with a pvalue<0.05. Otherwise, the two DMRs were viewed as 
independent. After iteratively merging interdependent DMRs, the final dataset of 
DMRs was made up of those that were independent from each other [17]. The 
DMR related genes was annotated with UCSC table browser tool [18,19]. 
3.3.2. KEGG Pathway Enrichment 
Pathway-based analysis helps to further understand genes biological 
functions. DAVID bioinformatics resources is used to analyze the pathway 
enrichment of DMR -related genes [20–22]. This analysis identifies significantly 
enriched metabolic pathways or signal transduction pathways in DMR -related 
genes comparing with the target regions background. 
3.3.3. Western Blotting 
The whole lysates of cells cultured in various conditions subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein concentration in 
whole cell lysates was determined by BCA protein assay kit (Thermo Scientific;23235, 
USA). The protein was transferred from gel to polyvinylidene difluoride (PVDF) 
membrane (Merck Millipore, Germany) and probed with Antibodies against anit-Akt and 
anit-p-Akt (Ser473), anit-p110γ (D55D5), anit-p101 (D32A5) (Cell Signaling 
CHAPTER 3 
 
63 
Technology, USA) at a 1:1000 dilution followed by horseradish peroxidase-conjugated 
secondary antibodies (1: 2,000-1: 5,000, Cell signaling Technology).  In -LIF experiment, 
miPSCs were cultured in miPSC medium without LIF for 6 hours before protein 
extraction. Immune-complex signals were developed with an ECL kit (PerkinElmer Inc., 
USA) and detected by Light Capture II (ATTO, Japan). 
3.3.4. RNA extraction, cDNA synthesis and qPCR mRNA expression analysis 
Total RNA was extracted using RNAeasy Mini kit (QUIAGEN, Germany) according 
to the manufacturer's instructions and 1 μg of RNA was reverse transcribed using 
Superscript First strand kit (Invitrogen, CA). Quantitative real time PCR was performed 
with cycler 480 SYBR green I Master Mix (Roche, Switzerland) according to 
manufacturer’s instructions. Primers used for qPCR are listed in Table 3.3. 
Table 3.3. List of Primers Used in the Experiments 
No Names Forward Primer Sequence Reverse Primer Sequence 
1 TCF7 GCGCGGGATAACTACGGAAA ACTGTCATCGGAAGGAACGG 
2 Epas1 AGACACCCCAGGGAACACTA TCACTGAAGTCCGTCTGGGT 
3 HDAC1 CTGTGAACTACCCACTGCGA TGGCGTGTCCTTTGATGGTC 
4 Cs2fra GTCCTCAACTCCACGGGTCA CTCGAGCGCCTTCGTAGC 
5 Wnt11 ACACTGTAAACAGCTGGAGGG CGTGTACCTCTCTCCAGGTCAA 
6 Abl1 ATCTCAGATGAGGTGGAGAAGG GTGTCAGGCGCATCTTTCTG 
7 CCND3 GATTCTGCACCGCCTGTCTC GATACATCGCAAAGGTGTAATCTGT 
8 Pik3ap1 GAAGGCCATTTCTGAAGATTCTGG TCTCGTCCAGCTTGCATCTC 
9 Thsb4 CCCAGCTGGACACTGACAAA TCCTACCCCGTCATTGTTGC 
10 Phllp1 GCCTGGAGCTGCTCAATAAC CTCTCGGTTGTCACGGAAGT 
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64 
11 Pik3r5 AAGTCCTTTGTCAGCAGTCCC CTGGTAAACCTGCAGCAACAC 
13 GADPH AACGGCACAGTCAAGGCCGA ACCCTTTTGGCTCCACCCTT 
 
3.3.4. STATISTICAL ANALYSIS 
The data were analyzed using two-tailed student’s t-test and are presented as the 
mean ± standard deviation (SD) at least three-time repetition. A P-values less than 
0.05 was considered to be statically significant, while less than 0.01 was highly 
significant. 
 
3.4. DISCUSSION 
The current study focused on the DNA methylation in the CSC model 
converted from iPSCs by the treatment with conditioned medium of cancer cells. 
In the conversion of pancreatic duct like adenocarcinoma (PDAC) like CSC model, 
there was no evidence relating to single point mutations even in Kras oncogene 
and its xenografts tumors showed the features of acinoductal metaplasia, 
pancreatic intraepithelial neoplasia and PDAC lesions[23]. We postulated that 
CSCs may be induced by epigenetic changes without any known mutations. 
Premature termination of reprogramming was reported to result in tumor 
development in various tissues with undifferentiated dysplastic cells exhibiting 
global changes in DNA methylation at H19 DMRs identifying IGF-2 expression 
up-regulated in the tumor initiating cells [24].  
Since the changes in DNA methylation was considered responsible for the 
conversion of iPSCs into CSCs, the patterns of DNA methylation were compared 
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between the converted cells (miPS-LLCcm cells), tumor derived cells (Ptdc cells 
and LMN cells) and miPSCs. As the results of bisulfite sequencing, we evaluated 
the list of epigenetically affected genes regarding to the DMRs in the miPS-LLCcm 
cells and Ptdc cells and LMN cells. Hypo- and hypermethylated genes were 
identified and hypomethylation was found overall superior to hypermethylation 
in all CSCs when compared to the parental cell line miPSCs. 
The analysis of KEGG pathways relating to hypomethylated genes revealed 
the several notable pathways important in cancers. Checking the expression of 
genes associated with these pathways, the expression of hypomethylated genes 
relating to PI3K-Akt pathway was found significantly high among those of the 
other genes. PI3K-Akt-mTOR signaling pathway has previously been reported as 
a key driver of carcinogenesis in several cancer types [25,26]. In this study, we 
found Pik3r5 (p101), which is a regulatory subunit of Pik3cg enzyme, as a 
hypomethylated and highly up-regulated gene relating to PI3K-Akt pathway. In 
the recent report, the evidence of PIK3CG as a potential oncogene were evaluated 
by analyzing the differential role each unit of PIK3CG, of which overexpression 
of the catalytic subunit PIK3CG (p110γ) or the regulatory subunit PIK3R5 (p101) 
leads to oncogenic cellular transformation and malignancy [27]. Therefore, the 
hypomethylation of Pik3r5 gene leading to the up-regulation is closely related to 
the activation/phosphorylation of AKT that is the downstream target molecule 
and Pik3cg should play a key role in carcinogenesis. In fact, the multiple myeloma 
cells derived from patients, the upregulation of PI3K components, in which 
PIK3CG has been proved to be a main regulator of cells adhesion and migration 
[28]. The PIK3CA gene has been reported to be hypomethylated in esophageal 
cancer cases when compared to the adjacent normal tissues [29]. On the other 
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hand, both Pik3r5 and Pik3cg were overexpressed resulting in the up-regulation 
of PI3K-gamma in the class IB PI3Ks, but not the PI3K-alpha in the class IA in our 
CSCs. Collectively, the activation of PI3K-Akt signaling pathway should 
significantly be relating with the conversion of miPSC into miPS-LLCcm cells 
resulting in the constitutive activation of Akt in Ptdc and LMN cells. 
According to the recent reports, the tumor cells produced a variety of 
molecules such as growth factors, cytokines and chemokines, which exhibited 
various effects such as on tumor growth and angiogenesis, providing them with 
various microenvironments [30,31]. In our study, we have successfully 
demonstrated the CSCs generated from iPSCs by the treatment with CM from 
cancer derived cells acquired the DNA hypomethylation.  
3.5. CONCLUSION 
Significant overall DNA hypomethylation during the conversion should 
lead to the activation of certain proto-oncogene, which represent the malignant 
conversion even without mutations. In this context, the hypomethylation might 
be considered to contribute to the progression and metastasis of the cancer stem 
cells. 
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Figure S1. Cumulative distribution of effective sequencing depth of 
cytosine. X axis represents the effective sequencing depth of C base 
while Y axis represents the cumulative percentage of C base at a 
certain sequencing depth.  
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Figure S2. The proportion of mCG, mCHG, and mCHH. Proportion 
of different methyl-cytosine patterns. The pie graph has three colors, 
each color represents one methylation type (mCG, mCHG, mCHH), 
and the area represent the proportion of the mC. 
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Figure S3. Methylation level distribution in CGI of four different 
stages of CSC cells, A. miPSC, B. miPS_LLCcm C. Primary Tumor 
Cells and D. Lung Nodules Cells. 
 
 
 
 
 
 
 
APPENDIX (Figure) 
 
 
77 
 
 
 
Figure S4. Trace data of codons in Pik3ca and Pten cDNA from miPSCs, 
miPS-LLCcm cells and Ptdc cells and LMN cells. The sequencing was 
carried out to cover the positions of codons that are frequently found 
mutated in human cancers, of the genes related to PI3K-Akt signaling 
pathway.  (A) The sequencing of Pik3ca cDNA showed that there is no 
point mutation at the codons of 542E, 545E and 1047H in all cells. (B) The 
sequencing of Pten cDNA showed that there is no point mutation at the 
codons of 130R, 173R and 233R in all cells. (DNA sequencing and position 
of the codons are shown at the top. Names of the cells are indicated on the 
left.) 
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Table S1. Data Summary and QC 
Samples Fragment Length (bp) 
Sequencing 
Strategy 
Clean Reads 
No. 
Clean Data 
Size (bp) 
Clean 
Rate (%) 
miPSCs 40~220 PE100 49108448 4910844800 68.01 
miPSC_LLCcm 40~220 PE100 43937308 4393730800 52.25 
Ptdc cells 40~220 PE100 39970510 3997051000 53.56 
LMN cells 40~220 PE100 37446394 3744639400 56.22 
Clean Rate (%) = Clean Data Size (bp)/Raw Data Size (bp) 
 
Table S2. Alignment statistics with reference genome 
 
 
Table S3. Proportion of mCG, mCHG and mCHH 
 
 
Table.4 Average methylation level of mC 
Elements Sample mC mCG mCHG mCHH 
promoter miPSC 40.284 34.435 51 77.191 
promoter LMT 31.599 19.609 73.415 89.364 
promoter Primary 31.812 21.657 65.687 84.684 
promoter miPSC_LLCcm 36.447 27.234 60.194 85.299 
CGI miPSC 25.096 19.885 34.435 72.689 
CGI LMT 21.944 12.049 40.52 82.521 
CGI Primary 30.165 18.334 75.403 88.583 
CGI miPSC_LLCcm 20.431 14.563 28.361 58.732 
 
 
Samples Clean Reads 
Mapped 
Reads 
Mapping 
Rate (%) 
Uniquely 
Mapped 
Reads 
Uniquely 
Mapping 
Rate (%) 
Enzyme 
Digestion 
Efficiency (%) 
miPSC 49108448 44488548 90.59 37885255 77.15 33.783 
miPSC_LLCcm 43937308 38450620 87.51 32873456 74.82 39.441 
Primary 39970510 36058878 90.21 30337853 75.9 57.898 
LMT 37446394 34785507 92.89 29131403 77.79 65.552 
 
in Promoter in CGI 
mCG mCHG mCHH mCG mCHG mCHH 
miPSC 
mC number 9310 896 2556 21144 2199 5254 
Proportion (%) 72.932 7.026 20.042 73.938 7.69 18.373 
miPS_LLCcm mC number 6703 832 2173 14846 2059 5026 
Proportion (%) 69.046 8.57 22.384 67.694 9.389 22.917 
Ptdc Cells mC number 3713 304 805 7550 871 2108 Proportion (%) 77.001 6.304 16.694 71.707 8.272 20.021 
LMN Cells mC number 3310 278 827 6800 793 2099 Proportion (%) 74.972 6.297 18.732 70.161 8.182 21.657 
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Table S5.  KEGG pathway analysis on hypomethylated DMR-associated 
genes (miPSCs Vs miPS-LLCcm cells) 
Category Term Count % PValue Genes 
KEGG_PATHWAY PI3K-Akt signaling pathway 17 4.009 0.00176 
FGFR2, PHLPP1, COL4A3, COL4A2, COL4A1, PDGFA, ITGA11, ITGB4, NR4A1, 
EPHA2, VWF, CCND3, ITGB6, PIK3R5, PIK3AP1, NGFR, THBS4 
KEGG_PATHWAY Pathways in cancer 17 4.009 0.00592 
FGFR2, COL4A3, TCF7, COL4A2, COL4A1, EPAS1, APC2, PDGFA, HDAC1, ADCY9, 
PLCG2, PTCH1, PIK3R5, WNT11, ABL1, CSF2RA, TRAF3 
KEGG_PATHWAY Focal adhesion 13 3.066 0.00090 
VWF, COL4A3, COL4A2, COL4A1, CCND3, PDGFA, ITGB6, ITGB4, ITGA11, 
PIK3R5, VAV2, PXN, THBS4 
KEGG_PATHWAY Calcium signaling pathway 11 2.594 0.00328 
GRM5, P2RX4, ADCY9, ERBB4, PDE1C, PLCG2, RYR1, PLCD3, CACNA1G, PLCD1, 
CAMK2B 
KEGG_PATHWAY ECM-receptor interaction 9 2.123 0.00036 VWF, COL4A3, COL4A2, COL4A1, ITGB6, ITGB4, ITGA11, SDC4, THBS4 
KEGG_PATHWAY Axon guidance 9 2.123 0.00432 ABLIM2, UNC5B, UNC5A, RGS3, NTNG1, ABL1, NTN1, EPHA2, EPHB2 
KEGG_PATHWAY Oxytocin signaling pathway 9 2.123 0.01404 
KCNJ6, ADCY9, RYR1, NPR1, PIK3R5, CAMK2B, CACNA2D2, CAMKK2, 
CACNA2D4 
KEGG_PATHWAY Proteoglycans in cancer 9 2.123 0.05150 ANK1, ERBB4, PLCG2, PIK3R5, WNT11, PTCH1, CAMK2B, SDC4, PXN 
KEGG_PATHWAY Regulation of actin cytoskeleton 9 2.123 0.06603 FGFR2, APC2, PDGFA, ITGB6, ITGB4, ITGA11, PIK3R5, VAV2, PXN 
KEGG_PATHWAY 
Aldosterone synthesis and 
secretion 8 1.887 0.00164 DAGLA, ADCY9, HSD3B5, CACNA1G, NPR1, NR4A1, CAMK2B, PRKCE 
KEGG_PATHWAY 
Transcriptional misregulation in 
cancer 8 1.887 0.04940 ERG, CEBPE, HDAC1, PDGFA, SUPT3, NGFR, FCGR1, KLF3 
KEGG_PATHWAY 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 7 1.651 0.00291 TCF7, DES, ITGB6, ITGB4, ITGA11, CACNA2D2, CACNA2D4 
KEGG_PATHWAY Dilated cardiomyopathy 7 1.651 0.00629 DES, ADCY9, ITGB6, ITGB4, ITGA11, CACNA2D2, CACNA2D4 
KEGG_PATHWAY 
Thyroid hormone signaling 
pathway 7 1.651 0.02589 HDAC1, PLCG2, ATP1A3, PLCD3, MED24, PLCD1, PIK3R5 
KEGG_PATHWAY 
Inflammatory mediator regulation 
of TRP channels 7 1.651 0.04095 ADCY9, P2RY2, ASIC4, PLCG2, PIK3R5, CAMK2B, PRKCE 
 
 
Table S6.  KEGG pathway analysis on hypomethylated DMR-associated 
genes (miPSCs Vs Ptdc cells) 
Category Term Count % PValue Genes 
KEGG_PATHWAY Metabolic pathways 18 5.901639344 0.403807798 PLD2, ME3, ALPPL2, KL, ALOX12E, HKDC1, CYP2J6, SGMS1, AGMAT, 
GGT5, GALM, SCLY, PYGL, PLCH2, MGAM, ATP6V0A1, FUK, ABO 
KEGG_PATHWAY Calcium signaling pathway 10 3.278688525 3.49E-04 P2RX4, ADCY4, ATP2A3, PDE1C, CACNA1G, GNAS, CAMK2B, 
CACNA1S, PTAFR, F2R 
KEGG_PATHWAY cAMP signaling pathway 8 2.62295082 0.010549721 PLD2, ADCY4, FFAR2, GNAS, CAMK2B, RAPGEF3, CACNA1S, F2R 
KEGG_PATHWAY Neuroactive ligand-receptor 
interaction 8 2.62295082 0.06103172 P2RX4, CHRM4, GRIK3, RXFP2, NPFFR1, PTAFR, CTSG, F2R 
KEGG_PATHWAY PI3K-Akt signaling pathway 8 2.62295082 0.140484875 VWF, COL4A3, YWHAG, PIK3AP1, NGFR, FGF1, F2R, ITGA2B 
KEGG_PATHWAY Pathways in cancer 8 2.62295082 0.215920682 COL4A3, ADCY4, PPARD, GNAS, FGF1, CSF2RA, F2R, ITGA2B 
KEGG_PATHWAY Oxytocin signaling pathway 7 2.295081967 0.013014035 ADCY4, KCNJ6, CACNB2, GNAS, CAMK2B, CACNA1S, MAP2K5 
KEGG_PATHWAY Rap1 signaling pathway 7 2.295081967 0.047927182 ADCY4, GNAS, RAPGEF3, NGFR, FGF1, F2R, ITGA2B 
KEGG_PATHWAY Glutamatergic synapse 6 1.967213115 0.013458719 PLD2, ADCY4, GRIK3, GNAS, SHANK1, SHANK2 
KEGG_PATHWAY Serotonergic synapse 6 1.967213115 0.023071277 KCNJ6, ALOX12E, CYP2J6, GNAS, RAPGEF3, CACNA1S 
KEGG_PATHWAY Adrenergic signaling in 
cardiomyocytes 6 1.967213115 0.037206634 ADCY4, CACNB2, GNAS, CAMK2B, RAPGEF3, CACNA1S 
KEGG_PATHWAY Dilated cardiomyopathy 5 1.639344262 0.018881129 ADCY4, CACNB2, GNAS, CACNA1S, ITGA2B 
KEGG_PATHWAY Aldosterone synthesis and 
secretion 5 1.639344262 0.021223303 ADCY4, CACNA1G, GNAS, CAMK2B, CACNA1S 
KEGG_PATHWAY Insulin secretion 5 1.639344262 0.021223303 ADCY4, FFAR1, GNAS, CAMK2B, CACNA1S 
KEGG_PATHWAY GABAergic synapse 5 1.639344262 0.022041932 PLCL1, ADCY4, KCNJ6, CACNA1S, NSF 
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Table S7.  KEGG pathway analysis on hypomethylated DMR-associated 
genes (miPSCs Vs LMN cells) 
Category Term Count % PValue Genes 
KEGG_PATHWAY PI3K-Akt signaling pathway 22 3.716216216 6.25E-05 FGFR2, PPP2R5D, ITGB4, NR4A1, EPHA2, ITGA9, YWHAG, LAMB3, LAMB2, VEGFA, GYS1, PDGFRB, CREB3L1, PIK3AP1, PIK3R5, NGFR, COL1A1, THBS1, ANGPT2, ITGA2B, 
FN1, F2R 
KEGG_PATHWAY Rap1 signaling pathway 15 2.533783784 4.55E-04 FGFR2, GNAO1, GRIN2A, EPHA2, VEGFA, PDGFRB, GNAS, RAPGEF4, PIK3R5, RAPGEF3, 
NGFR, THBS1, ANGPT2, ITGA2B, F2R 
KEGG_PATHWAY Pathways in cancer 15 2.533783784 0.079528386 FGFR2, PPARD, LAMB3, LAMB2, VEGFA, WNT9B, MAPK9, PDGFRB, GNAS, PIK3R5, 
ABL1, CSF2RA, ITGA2B, FN1, F2R 
KEGG_PATHWAY Axon guidance 14 2.364864865 8.69E-06 NTNG2, SLIT1, EPHB1, EPHA2, SLIT3, EPHB2, NCK2, SEMA5B, UNC5B, EPHA8, NFATC4, 
ROBO3, ABL1, NFATC2 
KEGG_PATHWAY cAMP signaling pathway 13 2.195945946 0.002133177 PLD2, FFAR2, ATP1A3, GRIN2A, NPR1, GRIA1, CREB3L1, MAPK9, GNAS, RAPGEF4, 
PIK3R5, RAPGEF3, F2R 
KEGG_PATHWAY Focal adhesion 13 2.195945946 0.003211744 ITGA9, LAMB3, LAMB2, VEGFA, ITGB4, MAPK9, PDGFRB, MYLK2, PIK3R5, COL1A1, 
THBS1, ITGA2B, FN1 
KEGG_PATHWAY Ras signaling pathway 12 2.027027027 0.017974152 FGFR2, PLD2, VEGFA, GRIN2A, MAPK9, PDGFRB, PIK3R5, NGFR, ABL1, PLA2G3, 
ANGPT2, EPHA2 
KEGG_PATHWAY Calcium signaling pathway 11 1.858108108 0.009277251 P2RX4, TNNC2, PDE1C, RYR1, GRIN2A, PLCD3, CACNA1G, PDGFRB, MYLK2, GNAS, F2R 
KEGG_PATHWAY Cytokine-cytokine receptor 
interaction 11 1.858108108 0.060185364 AMHR2, TNFRSF9, ACVR2B, LTBR, CXCR5, VEGFA, TNFRSF13B, PDGFRB, NGFR, CSF2RA, IL11 
KEGG_PATHWAY Oxytocin signaling pathway 10 1.689189189 0.011431376 GNAO1, RYR1, CACNB2, NPR1, MYLK2, GNAS, PIK3R5, NFATC4, NFATC2, CAMKK2 
KEGG_PATHWAY cGMP-PKG signaling 
pathway 10 1.689189189 0.018383555 GTF2I, GATA4, PDE5A, ATP1A3, NPR1, MYLK2, CREB3L1, PIK3R5, NFATC4, NFATC2 
KEGG_PATHWAY Regulation of actin 
cytoskeleton 10 1.689189189 0.062437352 FGFR2, ITGA9, CHRM4, ITGB4, PDGFRB, MYLK2, PIK3R5, F2R, ITGA2B, FN1 
KEGG_PATHWAY Dilated cardiomyopathy 9 1.52027027 6.64E-04 ITGA9, DES, MYBPC3, LMNA, ITGB4, CACNB2, GNAS, SGCA, ITGA2B 
KEGG_PATHWAY Adrenergic signaling in 
cardiomyocytes 9 1.52027027 0.023805439 PPP2R5D, ATP1A3, CACNB2, CREB3L1, GNAS, PIK3R5, RAPGEF4, RAPGEF3, SCN5A 
KEGG_PATHWAY Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) 8 1.351351351 0.00126012 ITGA9, DES, LMNA, ITGB4, CACNB2, DSP, SGCA, ITGA2B 
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